Amphastar Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. (ticker: AMPH) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States. Headquartered in Rancho Cucamonga, California, Amphastar describes itself as an integrated pharmaceutical company focused on developing, manufacturing, and commercializing technically challenging injectable, intranasal, and inhalation products, as well as active pharmaceutical ingredients (APIs). The company was incorporated in California in 1996 and has since expanded through acquisitions and internal platform development. ([amphastar.com](https://www.amphastar.com/about-us.html?utm_source=openai)) From an equity-analysis perspective, Amphastar’s business model combines an established commercial base with a pipeline designed to deepen its presence in specialized generics and biologics. The company sells more than 25 prescription products plus one over-the-counter product, Primatene MIST®, and its largest revenue contributors currently include BAQSIMI® glucagon nasal powder, Primatene MIST®, glucagon, epinephrine, and lidocaine. Management also highlights development programs spanning ANDAs, BLAs, and biosimilar insulin candidates, which positions Amphastar as more than a traditional commodity-generic manufacturer: it is pursuing a higher-complexity product mix with stronger barriers to entry. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm?utm_source=openai)) Amphastar’s competitive edge comes from manufacturing complexity and formulation expertise rather than scale alone. The company emphasizes expertise in sterile injectables, emergency medicines, and specialty delivery formats, areas where regulatory compliance, process control, and supply reliability matter greatly. It also states that it operates five manufacturing facilities across the United States, China, and Europe, along with an advanced research center, while all finished products are manufactured in the United States. That footprint supports quality, redundancy, and customer trust, but the company remains exposed to pricing pressure in mature generics and to competition in key hospital-oriented products. ([amphastar.com](https://www.amphastar.com/about-us.html?utm_source=openai)) Recent developments have been important for the investment case. Amphastar’s BAQSIMI® franchise was strengthened by the 2023 acquisition of the product, and in early 2025 the company assumed full global distribution responsibilities, helping revenue recognition and giving Amphastar greater control over the brand’s commercial rollout. The company also continued to refresh its portfolio with launches such as albuterol in 2024 and iron sucrose in 2025. In July 2025, Amphastar announced a multi-year expansion of U.S. manufacturing capacity at its Rancho Cucamonga headquarters, which it characterized as the largest domestic infrastructure investment in its history. These actions suggest a clear strategic focus on supply-chain control, capacity expansion, and strengthening its specialty-product franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm?utm_source=openai))